CervoMed (NASDAQ:CRVO - Free Report) had its price objective boosted by Roth Mkm from $15.00 to $20.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.
Other equities analysts have also issued research reports about the company. HC Wainwright lowered CervoMed from a "buy" rating to a "neutral" rating in a research note on Tuesday, December 17th. Brookline Capital Management raised shares of CervoMed from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 11th. Morgan Stanley reaffirmed an "underweight" rating on shares of CervoMed in a research note on Wednesday, December 11th. Jones Trading raised shares of CervoMed from a "hold" rating to a "buy" rating and set a $15.00 target price for the company in a research note on Thursday, March 13th. Finally, Canaccord Genuity Group lifted their target price on CervoMed from $12.00 to $21.00 and gave the company a "buy" rating in a report on Tuesday. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, CervoMed presently has an average rating of "Moderate Buy" and an average target price of $27.50.
View Our Latest Stock Analysis on CRVO
CervoMed Price Performance
Shares of NASDAQ:CRVO traded up $2.73 during midday trading on Tuesday, hitting $14.29. The company had a trading volume of 7,288,342 shares, compared to its average volume of 1,218,899. CervoMed has a 12-month low of $1.80 and a 12-month high of $25.92. The company has a market cap of $88.17 million, a price-to-earnings ratio of -7.04 and a beta of 1.84. The company has a fifty day moving average of $3.30 and a two-hundred day moving average of $7.81.
CervoMed (NASDAQ:CRVO - Get Free Report) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The business had revenue of $2.16 million during the quarter, compared to the consensus estimate of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. Research analysts expect that CervoMed will post -1.88 earnings per share for the current fiscal year.
Institutional Trading of CervoMed
Hedge funds have recently modified their holdings of the company. Woodline Partners LP bought a new stake in CervoMed in the fourth quarter valued at about $175,000. Nuveen Asset Management LLC increased its holdings in CervoMed by 113.6% during the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company's stock worth $97,000 after buying an additional 22,104 shares during the last quarter. BNP Paribas Financial Markets bought a new stake in CervoMed in the 4th quarter valued at $32,000. Mariner LLC acquired a new position in CervoMed in the 4th quarter valued at about $30,000. Finally, DRW Securities LLC bought a new stake in CervoMed in the 4th quarter valued at $30,000. Institutional investors and hedge funds own 25.15% of the company's stock.
CervoMed Company Profile
(
Get Free Report)
CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
Featured Articles
Before you consider CervoMed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CervoMed wasn't on the list.
While CervoMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
